Literature DB >> 9486971

All-trans retinoic acid converts E2F into a transcriptional suppressor and inhibits the growth of normal human bronchial epithelial cells through a retinoic acid receptor- dependent signaling pathway.

H Y Lee1, D F Dohi, Y H Kim, G L Walsh, U Consoli, M Andreeff, M I Dawson, W K Hong, J M Kurie.   

Abstract

Retinoids, including retinol and retinoic acid derivatives, maintain the normal growth and differentiation of human bronchial epithelial (HBE) cells and are under investigation as agents for lung cancer prevention. In this study, we examined the biologic effects of retinoids on normal HBE cells and the molecular mechanisms of retinoid actions. At a dose of 10(-6) M, all-trans retinoic acid (t-RA) suppressed the proliferation of normal HBE cells, which accumulated in the G0 phase. No evidence of programmed cell death was observed. The class of retinoid nuclear receptor that mediated the growth arrest was explored. Normal HBE cell growth was suppressed by a retinoid that selectively activates retinoic acid receptors but not by one that activates retinoid X receptors. The E2F transcription factor has demonstrated a role in G0 entry through transcriptional suppression of genes that induce cell cycle progression. To investigate the role of E2F in retinoid signaling, transient transfection assays were performed using reporter plasmids containing E2F-binding sites. Findings from these experiments suggested that t-RA treatment converted E2F into a transcriptional suppressor. Supporting this possibility, t-RA inhibited the expression of the E2F target genes B-myb, cyclin A, and cyclin E. Further, t-RA increased the levels of nuclear E2F-4, p107, and p130 and enhanced the binding of E2F-4 to p107, which have been associated with the conversion of E2F into a transcriptional suppressor in other cells. These findings point to retinoic acid receptor- and E2F-dependent pathways as potential mediators of retinoid-induced growth arrest in normal HBE cells and have implications for the use of retinoids in clinical trials on the prevention of lung cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9486971      PMCID: PMC508652          DOI: 10.1172/JCI1329

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  59 in total

1.  Nuclear receptor that identifies a novel retinoic acid response pathway.

Authors:  D J Mangelsdorf; E S Ong; J A Dyck; R M Evans
Journal:  Nature       Date:  1990-05-17       Impact factor: 49.962

Review 2.  A human retinoic acid receptor which belongs to the family of nuclear receptors.

Authors:  M Petkovich; N J Brand; A Krust; P Chambon
Journal:  Nature       Date:  1987 Dec 3-9       Impact factor: 49.962

3.  Identification of a receptor for the morphogen retinoic acid.

Authors:  V Giguere; E S Ong; P Segui; R M Evans
Journal:  Nature       Date:  1987 Dec 17-23       Impact factor: 49.962

4.  A third human retinoic acid receptor, hRAR-gamma.

Authors:  A Krust; P Kastner; M Petkovich; A Zelent; P Chambon
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

5.  The differentiation potential of tracheal basal cells.

Authors:  Y Inayama; G E Hook; A R Brody; G S Cameron; A M Jetten; L B Gilmore; T Gray; P Nettesheim
Journal:  Lab Invest       Date:  1988-06       Impact factor: 5.662

6.  Regulation of proliferation and differentiation of respiratory tract epithelial cells by TGF beta.

Authors:  A M Jetten; J E Shirley; G Stoner
Journal:  Exp Cell Res       Date:  1986-12       Impact factor: 3.905

7.  Identification of a second human retinoic acid receptor.

Authors:  N Brand; M Petkovich; A Krust; P Chambon; H de Thé; A Marchio; P Tiollais; A Dejean
Journal:  Nature       Date:  1988-04-28       Impact factor: 49.962

8.  Characterization of three RXR genes that mediate the action of 9-cis retinoic acid.

Authors:  D J Mangelsdorf; U Borgmeyer; R A Heyman; J Y Zhou; E S Ong; A E Oro; A Kakizuka; R M Evans
Journal:  Genes Dev       Date:  1992-03       Impact factor: 11.361

9.  Retinoid X receptor is an auxiliary protein for thyroid hormone and retinoic acid receptors.

Authors:  X K Zhang; B Hoffmann; P B Tran; G Graupner; M Pfahl
Journal:  Nature       Date:  1992-01-30       Impact factor: 49.962

10.  Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling.

Authors:  S A Kliewer; K Umesono; D J Mangelsdorf; R M Evans
Journal:  Nature       Date:  1992-01-30       Impact factor: 49.962

View more
  6 in total

1.  GRIM-19 and p16(INK4a) synergistically regulate cell cycle progression and E2F1-responsive gene expression.

Authors:  Peng Sun; Shreeram C Nallar; Abhijit Raha; Sudhakar Kalakonda; Chidambaram N Velalar; Sekhar P Reddy; Dhananjaya V Kalvakolanu
Journal:  J Biol Chem       Date:  2010-06-03       Impact factor: 5.157

2.  All-trans-retinoic acid inhibits Jun N-terminal kinase by increasing dual-specificity phosphatase activity.

Authors:  H Y Lee; N Sueoka; W K Hong; D J Mangelsdorf; F X Claret; J M Kurie
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

3.  A pediatric surgeon retools in genetics and genomics to study congenital diaphragmatic hernia.

Authors:  Patricia K Donahoe
Journal:  J Pediatr Surg       Date:  2009-02       Impact factor: 2.545

4.  Dominant negative retinoic acid receptor initiates tumor formation in mice.

Authors:  Tara S Kupumbati; Giorgio Cattoretti; Christine Marzan; Eduardo F Farias; Reshma Taneja; Rafael Mira-y-Lopez
Journal:  Mol Cancer       Date:  2006-03-24       Impact factor: 27.401

5.  A neuronal-specific differentiation protein that directly modulates retinoid receptor transcriptional activation.

Authors:  Kenneth W Henry II; Michael L Spencer; Maria Theodosiou; Dingyuan Lou; Daniel J Noonan
Journal:  Nucl Recept       Date:  2003-09-10

Review 6.  Retinoic Acids in the Treatment of Most Lethal Solid Cancers.

Authors:  Lara Costantini; Romina Molinari; Barbara Farinon; Nicolò Merendino
Journal:  J Clin Med       Date:  2020-01-28       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.